Astrazeneca Receives First European Approval For Nexium(R) In Pediatric Gerd

AstraZeneca announced that it has received Swedish Medical Products Agency (MPA) approval for use of Nexium(R) (esomeprazole) in children aged 1-11 years with gastroesophageal reflux disease (GERD) in the reference member state of Sweden, with other European Union nations expected to follow.1 Nexium® will become the first of the proton pump inhibitors (PPI) currently available for the treatment of pediatric GERD to have a specific formulation developed for children. [click link for full article]

More: continued here

Filed under: Acid Reflux/GERD on December 2nd, 2007